Moderna Stock Soars Over 90% in Premarket After Phase 3 Trial Success
Moderna's stock surged over 90% in premarket trading on Wednesday after the company, in partnership with Merck, reported successful results from a Phase 3 trial of their personalized mRNA cancer treatment for melanoma. Shares of Merck also saw an increase of about 7% prior to market opening.
The INTerpath-001 trial, which tested the personalized mRNA cancer vaccine intismeran autogene, showed significant improvements in both recurrence-free survival and distant metastasis-free survival at a planned interim analysis. These results were deemed statistically significant and clinically meaningful for patients with completely removed stage IIB, IIC, III, or IV melanoma who had not previously undergone systemic therapy. The trial will continue to monitor patients for additional outcomes, including overall survival.
For Your Trading Desk
Sponsor Spike Success.
This milestone marks the first successful Phase 3 result for individualized neoantigen therapy and an mRNA-based cancer treatment. It is also the first Phase 3 trial to show a meaningful benefit over Merck's KEYTRUDA alone for patients receiving treatment after melanoma surgery.
Intismeran autogene, also known as V940/mRNA-4157, is a cancer vaccine tailored to each patient. Researchers identify unique mutations in the patient's tumor and develop an mRNA treatment designed to train the immune system to recognize and attack those cancer cells. This treatment is being jointly developed by Moderna and Merck.
Both companies plan to present the full findings at an upcoming international medical meeting and will engage with regulators regarding potential submissions for the combination therapy. If the detailed data corroborate the topline findings, this treatment could pave the way for personalized cancer vaccines as a new option for patients post-surgery.
The latest results follow encouraging Phase 2b findings from the KEYNOTE-942/mRNA-4157-P201 trial, where five-year data presented at ASCO 2026 indicated that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to KEYTRUDA alone, and decreased the risk of distant cancer spread or death by 59%.
Currently, the companies are conducting nine Phase 2 and Phase 3 trials for intismeran across various cancers, including melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, with additional studies exploring pancreatic and gastric cancers, as well as different applications of the treatment in lung cancer.




